366 related articles for article (PubMed ID: 33180138)
1. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas.
Singh G; Xu H
Lab Med; 2021 Jul; 52(4):390-398. PubMed ID: 33180138
[TBL] [Abstract][Full Text] [Related]
2. Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations.
Lee WS; Singh G
Lab Med; 2019 Oct; 50(4):381-389. PubMed ID: 30957173
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas.
Singh G
Lab Med; 2019 Apr; 50(2):189-193. PubMed ID: 30423164
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
5. Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease.
Singh G; Arinze N; Manthei DM; Plapp FV; Bollag RJ
Lab Med; 2023 Sep; 54(5):527-533. PubMed ID: 36857478
[TBL] [Abstract][Full Text] [Related]
6. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
Evliyaoglu O; van Helden J; Jaruschewski S; Imöhl M; Weiskirchen R
Clin Biochem; 2019 Dec; 74():42-46. PubMed ID: 31526775
[TBL] [Abstract][Full Text] [Related]
7. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
9. A rare case of IgE kappa monoclonal gammopathy of undetermined significance identified in a Swedish female.
Fager Ferrari M; Lemonakis K; Förnvik Jonsson M
Scand J Clin Lab Invest; 2021 Sep; 81(5):385-388. PubMed ID: 34097568
[TBL] [Abstract][Full Text] [Related]
10. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
11. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.
Baldini L; Guffanti A; Cesana BM; Colombi M; Chiorboli O; Damilano I; Maiolo AT
Blood; 1996 Feb; 87(3):912-8. PubMed ID: 8562962
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Free Immunoglobulin Light Chains in Urine.
Singh G; Cotter T; Ye Mon M; Xu H; Bollag RJ
J Appl Lab Med; 2023 Nov; 8(6):1101-1114. PubMed ID: 37725944
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Significance of Serum Free Light Chain in Monoclonal Gammopathy].
Lu H; Zhang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):155-158. PubMed ID: 38387914
[TBL] [Abstract][Full Text] [Related]
16. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
Singh G
J Appl Lab Med; 2020 Nov; 5(6):1358-1371. PubMed ID: 33150391
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
18. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Singh G; Bollag R
Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
[TBL] [Abstract][Full Text] [Related]
19. [AL amyloidosis presenting with fluminant multiorgan failure accompanied by rapid progression from MGUS to multiple myeloma].
Tazoe K; Takakuwa T; Makuuchi Y; Kuno M; Harada N; Okamura H; Nishimoto M; Koh H; Nakashima Y; Nakamae H; Hino M
Rinsho Ketsueki; 2022; 63(1):31-36. PubMed ID: 35135949
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
